640 related articles for article (PubMed ID: 26976826)
21. Regulation of Memory CD8+ T Cell Differentiation by MicroRNAs.
Zhang Z; Zhang C; Li F; Zhang B; Zhang Y
Cell Physiol Biochem; 2018; 47(6):2187-2198. PubMed ID: 30011396
[TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T cell persistence and memory cell formation.
McLellan AD; Ali Hosseini Rad SM
Immunol Cell Biol; 2019 Aug; 97(7):664-674. PubMed ID: 31009109
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
24. Origin of CD8+ effector and memory T cell subsets.
Stemberger C; Neuenhahn M; Buchholz VR; Busch DH
Cell Mol Immunol; 2007 Dec; 4(6):399-405. PubMed ID: 18163951
[TBL] [Abstract][Full Text] [Related]
25. Effector CD4 T cells are biochemically distinct from the memory subset: evidence for long-term persistence of effectors in vivo.
Ahmadzadeh M; Hussain SF; Farber DL
J Immunol; 1999 Sep; 163(6):3053-63. PubMed ID: 10477569
[TBL] [Abstract][Full Text] [Related]
26. The use of endogenous T cells for adoptive transfer.
Yee C
Immunol Rev; 2014 Jan; 257(1):250-63. PubMed ID: 24329802
[TBL] [Abstract][Full Text] [Related]
27. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Hinrichs CS; Borman ZA; Cassard L; Gattinoni L; Spolski R; Yu Z; Sanchez-Perez L; Muranski P; Kern SJ; Logun C; Palmer DC; Ji Y; Reger RN; Leonard WJ; Danner RL; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 2009 Oct; 106(41):17469-74. PubMed ID: 19805141
[TBL] [Abstract][Full Text] [Related]
28. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.
Crompton JG; Sukumar M; Restifo NP
Immunol Rev; 2014 Jan; 257(1):264-276. PubMed ID: 24329803
[TBL] [Abstract][Full Text] [Related]
29. Adoptive immunotherapy for cancer.
Ruella M; Kalos M
Immunol Rev; 2014 Jan; 257(1):14-38. PubMed ID: 24329787
[TBL] [Abstract][Full Text] [Related]
30. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
Ikeda H
Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
[TBL] [Abstract][Full Text] [Related]
31. Adoptive T-cell immunotherapy of cancer.
Li Q; Chang AE
Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
[TBL] [Abstract][Full Text] [Related]
32. Leishmania infantum antigens modulate memory cell subsets of liver resident T lymphocyte.
Rodrigues A; Claro M; Alexandre-Pires G; Santos-Mateus D; Martins C; Valério-Bolas A; Rafael-Fernandes M; Pereira MA; Pereira da Fonseca I; Tomás AM; Santos-Gomes G
Immunobiology; 2017 Feb; 222(2):409-422. PubMed ID: 27615509
[TBL] [Abstract][Full Text] [Related]
33. Human cell-based artificial antigen-presenting cells for cancer immunotherapy.
Butler MO; Hirano N
Immunol Rev; 2014 Jan; 257(1):191-209. PubMed ID: 24329798
[TBL] [Abstract][Full Text] [Related]
34. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
Houot R; Schultz LM; Marabelle A; Kohrt H
Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
[TBL] [Abstract][Full Text] [Related]
35. Exploiting cytokines in adoptive T-cell therapy of cancer.
Petrozziello E; Sturmheit T; Mondino A
Immunotherapy; 2015; 7(5):573-84. PubMed ID: 26065481
[TBL] [Abstract][Full Text] [Related]
36. Enhancing adoptive T cell immunotherapy with microRNA therapeutics.
Ji Y; Hocker JD; Gattinoni L
Semin Immunol; 2016 Feb; 28(1):45-53. PubMed ID: 26710685
[TBL] [Abstract][Full Text] [Related]
37. Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy.
Xu Y; Dotti G
J Clin Invest; 2016 Jan; 126(1):35-7. PubMed ID: 26657855
[TBL] [Abstract][Full Text] [Related]
38. Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy.
Rolle CE; Carrio R; Malek TR
Cancer Res; 2008 Apr; 68(8):2984-92. PubMed ID: 18413768
[TBL] [Abstract][Full Text] [Related]
39. A Context-Dependent Role for IL-21 in Modulating the Differentiation, Distribution, and Abundance of Effector and Memory CD8 T Cell Subsets.
Tian Y; Cox MA; Kahan SM; Ingram JT; Bakshi RK; Zajac AJ
J Immunol; 2016 Mar; 196(5):2153-66. PubMed ID: 26826252
[TBL] [Abstract][Full Text] [Related]
40. Tissue-resident memory T cells.
Schenkel JM; Masopust D
Immunity; 2014 Dec; 41(6):886-97. PubMed ID: 25526304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
